Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 23

Sort by

Sort Order Select

Journal Articles

Allogeneic stem cell transplantation compared to conservative management in adults with inborn errors of immunity

Blood (2023) 141 (1): 60–71.

https://doi.org/10.1182/blood.2022015482

Published: 2023

Includes: Supplemental data

Journal Articles

Hematopoietic stem cell transplantation for adolescents and adults with inborn errors of immunity: an EBMT IEWP study

Blood (2022) 140 (14): 1635–1649.

https://doi.org/10.1182/blood.2022015506

Published: 2022

Includes: Supplemental data

Journal Articles

Long-Term Follow-up Study after Lentiviral Hematopoietic Stem/Progenitor Cell Gene Therapy for Wiskott - Aldrich Syndrome

Blood (2021) 138 (Supplement 1): 2934.

https://doi.org/10.1182/blood-2021-147697

Published: 2021

Journal Articles

How I use allogeneic HSCT for adults with inborn errors of immunity

Siobhan O. Burns, Emma C. Morris

Blood (2021) 138 (18): 1666–1676.

https://doi.org/10.1182/blood.2020008187

Published: 2021

Includes: Supplemental data

Journal Articles

HCT for CGD? Yes, and the sooner the better

Emma C. Morris

Blood (2020) 136 (10): 1121–1123.

https://doi.org/10.1182/blood.2020007891

Published: 2020

Journal Articles

A Phase I Study Evaluating the Safety and Persistence of Allorestricted WT1-TCR Gene Modified Autologous T Cells in Patients with High-Risk Myeloid Malignancies Unsuitable for Allogeneic Stem Cell Transplantation

Blood (2019) 134 (Supplement_1): 1367.

https://doi.org/10.1182/blood-2019-128044

Published: 2019

Journal Articles

Editing gene engineering to enhance function

Emma C. Morris

Blood (2018) 131 (3): 272–273.

https://doi.org/10.1182/blood-2017-11-816587

Published: 2018

Journal Articles

Gene therapy for Wiskott-Aldrich syndrome in a severely affected adult

Blood (2017) 130 (11): 1327–1335.

https://doi.org/10.1182/blood-2017-04-777136

Published: 2017

Includes: Supplemental data

Journal Articles

Successful Outcome Following Allogeneic Haematopoietic Stem Cell Transplantation in Adults with Inherited Primary Immunodeficiency (PID)

Emma C Morris, MD PhD, Thomas Andrew Fox, MRCP, Siobhan Burns, MD PhD, Ben Carpenter, MD, Kirsty J Thomson, MD, David Lowe, MD PhD, Adele K. Fielding, MB BS, PhD FRCP, FRCPath, Karl S Peggs, MD, Panagiotis Kottaridis, FRCPath, PhD MSc, Victoria Grandage, FRCPath, MRCP, PhD, Shari Denovan, RN, Sarah Grace, RN, Julia Dahlstrom, RN, Sarita Workman, RN, Andrew Symes, RN, Stephen Mackinnon, MD, Ronjon Chakraverty, BMBS, PhD, Rachael Hough, MD BMBS, FRCP, FRCPath

Blood (2016) 128 (22): 4681.

https://doi.org/10.1182/blood.V128.22.4681.4681

Published: 2016

Journal Articles

Optimizing T-cell receptor gene therapy for hematologic malignancies

Emma C. Morris, Hans J. Stauss

Blood (2016) 127 (26): 3305–3311.

https://doi.org/10.1182/blood-2015-11-629071

Published: 2016

Journal Articles

Human T cells expressing affinity-matured TCR display accelerated responses but fail to recognize low density of MHC-peptide antigen

Sharyn Thomas, Shao-An Xue, Charles R. M. Bangham, Bent K. Jakobsen, Emma C. Morris, Hans J. Stauss

Blood (2011) 118 (2): 319–329.

https://doi.org/10.1182/blood-2010-12-326736

Published: 2011

Journal Articles

Specificity for the tumor-associated self-antigen WT1 drives the development of fully functional memory T cells in the absence of vaccination

Constandina Pospori, Shao-An Xue, Angelika Holler, Cecile Voisine, Mario Perro, Judith King, Farnaz Fallah-Arani, Barry Flutter, Ronjon Chakraverty, Hans J. Stauss, Emma C. Morris

Blood (2011) 117 (25): 6813–6824.

https://doi.org/10.1182/blood-2010-08-304568

Published: 2011

Journal Articles

HLA-mismatched unrelated donors are a viable alternate graft source for allogeneic transplantation following alemtuzumab-based reduced-intensity conditioning

Adam J. Mead, Kirsty J. Thomson, Emma C. Morris, Sajir Mohamedbhai, Shari Denovan, Guillermo Orti, Adele K. Fielding, Panagiotis D. Kottaridis, Rachael Hough, Ronjon Chakraverty, David C. Linch, Stephen Mackinnon, Karl S. Peggs

Blood (2010) 115 (25): 5147–5153.

https://doi.org/10.1182/blood-2010-01-265413

Published: 2010

Includes: Supplemental data

Journal Articles

Prognostic role of PET scanning before and after reduced-intensity allogeneic stem cell transplantation for lymphoma

Jonathan R. Lambert, Jamshed B. Bomanji, Karl S. Peggs, Kirsty J. Thomson, Ronjon K. Chakraverty, Adele K. Fielding, Panagiotis D. Kottaridis, Michael Roughton, Emma C. Morris, Anthony H. Goldstone, David C. Linch, Peter J. Ell, Stephen Mackinnon

Blood (2010) 115 (14): 2763–2768.

https://doi.org/10.1182/blood-2009-11-255182

Published: 2010

Journal Articles

Mismatch at 1-2 HLA Loci Does Not Reduce Survival Following Alemtuzumab-Based Reduced Intensity Unrelated Donor Allogeneic Transplantation

Adam J Mead, Kirsty J Thomson, Emma C Morris, Ronjon Chakraverty, David C. Linch, FRCP, Stephen Mackinnon, MD, Karl S Peggs

Blood (2008) 112 (11): 3008.

https://doi.org/10.1182/blood.V112.11.3008.3008

Published: 2008

Journal Articles

LMP2-Specific TCR Gene Therapy for Hodgkin Lymphoma - Design of a Dominant TCR Construct for Immunotherapy.

Daniel P. Hart, MD, Sharyn Thomas, Shao-an Xue, Emma C. Morris, MD, PhD, Hans J. Stauss, MD, PhD

Blood (2007) 110 (11): 2762.

https://doi.org/10.1182/blood.V110.11.2762.2762

Published: 2007

Journal Articles

Allogeneic Stem Cell Transplantation for High-Risk Acute Myeloid Leukemia: No Increase in Relapse with Alemtuzumab-Depleted Grafts.

Kirsty J. Thomson, MD, Karl S. Peggs, MD, Emma C. Morris, MD, Asim Khwaja, MD, David C. Linch, MD, Anthony H. Goldstone, MD, Stephen Mackinnon, MD

Blood (2005) 106 (11): 2053.

https://doi.org/10.1182/blood.V106.11.2053.2053

Published: 2005

Journal Articles

Reduced Intensity Allogeneic Transplantation for Non-Hodgkin’s Lymphoma: Extended Follow-Up of an Alemtuzumab-Containing Regimen.

Kirsty J. Thomson, MD, Emma C. Morris, MD, Don Milligan, MD, Gordon Cook, MD, Jim Cavet, MD, Charles Craddock, MD, Ann Hunter, MD, Steve Schey, MD, Anne Parker, MD, Anthony H. Goldstone, MD, David C. Linch, MD, Karl S. Peggs, MD, Stephen Mackinnon, MD

Blood (2005) 106 (11): 401.

https://doi.org/10.1182/blood.V106.11.401.401

Published: 2005

Journal Articles

Improved Outcome Following Reduced Intensity Allogeneic Transplantation in Hodgkin’s Lymphoma Relapsing Post-Autologous Transplantation.

Kirsty J. Thomson, MD, Karl S. Peggs, MD, Paul Smith, MSc, Raj Chopra, MD, Jim Cavet, MD, Ann Hunter, MD, Anne Parker, MD, Ruth Pettengell, MD, Don Milligan, MD, Emma C. Morris, MD, Anthony H. Goldstone, MD, David C. Linch, MD, Stephen Mackinnon, MD

Blood (2005) 106 (11): 657.

https://doi.org/10.1182/blood.V106.11.657.657

Published: 2005

Journal Articles

Dose-escalated donor lymphocyte infusions following reduced intensity transplantation: toxicity, chimerism, and disease responses

Karl S. Peggs, Kirsty Thomson, Daniel P. Hart, Johanne Geary, Emma C. Morris, Kwee Yong, Anthony H. Goldstone, David C. Linch, Stephen Mackinnon

Blood (2004) 103 (4): 1548–1556.

https://doi.org/10.1182/blood-2003-05-1513

Published: 2004

NARROW

Allogeneic stem cell transplantation compared to conservative management in adults with inborn errors of immunity

Hematopoietic stem cell transplantation for adolescents and adults with inborn errors of immunity: an EBMT IEWP study

Long-Term Follow-up Study after Lentiviral Hematopoietic Stem/Progenitor Cell Gene Therapy for Wiskott - Aldrich Syndrome

How I use allogeneic HSCT for adults with inborn errors of immunity

HCT for CGD? Yes, and the sooner the better

A Phase I Study Evaluating the Safety and Persistence of Allorestricted WT1-TCR Gene Modified Autologous T Cells in Patients with High-Risk Myeloid Malignancies Unsuitable for Allogeneic Stem Cell Transplantation

Editing gene engineering to enhance function

Gene therapy for Wiskott-Aldrich syndrome in a severely affected adult

Successful Outcome Following Allogeneic Haematopoietic Stem Cell Transplantation in Adults with Inherited Primary Immunodeficiency (PID)

Optimizing T-cell receptor gene therapy for hematologic malignancies

Human T cells expressing affinity-matured TCR display accelerated responses but fail to recognize low density of MHC-peptide antigen

Specificity for the tumor-associated self-antigen WT1 drives the development of fully functional memory T cells in the absence of vaccination

HLA-mismatched unrelated donors are a viable alternate graft source for allogeneic transplantation following alemtuzumab-based reduced-intensity conditioning

Prognostic role of PET scanning before and after reduced-intensity allogeneic stem cell transplantation for lymphoma

Mismatch at 1-2 HLA Loci Does Not Reduce Survival Following Alemtuzumab-Based Reduced Intensity Unrelated Donor Allogeneic Transplantation

LMP2-Specific TCR Gene Therapy for Hodgkin Lymphoma - Design of a Dominant TCR Construct for Immunotherapy.

Allogeneic Stem Cell Transplantation for High-Risk Acute Myeloid Leukemia: No Increase in Relapse with Alemtuzumab-Depleted Grafts.

Reduced Intensity Allogeneic Transplantation for Non-Hodgkin’s Lymphoma: Extended Follow-Up of an Alemtuzumab-Containing Regimen.

Improved Outcome Following Reduced Intensity Allogeneic Transplantation in Hodgkin’s Lymphoma Relapsing Post-Autologous Transplantation.

Dose-escalated donor lymphocyte infusions following reduced intensity transplantation: toxicity, chimerism, and disease responses

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only